Disease Domain | Count |
---|---|
Neoplasms | 1 |
Hemic and Lymphatic Diseases | 1 |
Nervous System Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Mesenchymal stem cell therapy | 1 |
Shared antigen vaccine | 1 |
Cell therapy | 1 |
Immune cell therapy | 1 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date29 Apr 2010 |
Target- |
Mechanism Cell replacements |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Cell replacements |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Aug 2023 |
Sponsor / Collaborator |
Start Date28 May 2023 |
Sponsor / Collaborator |
Start Date25 May 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Sipuleucel-T (Dendreon Corporation) | Metastatic castration-resistant prostate cancer More | Approved |
Human umbilical cord mesenchymal stem cells(Shandong Qilu Stem Cells) | Bone Marrow Failure Disorders More | Phase 2 Clinical |
Human cord blood-derived mononuclear cells(Shandong Qilu Stem Cells Engineering) | Hypoxia-Ischemia, Brain More | Clinical |
CVS-2288 ( thrombin ) | Thrombosis More | Discontinued |
CVS-2038 ( thrombin ) | Thrombosis More | Discontinued |